Oxford, UK-based Immunocore, which is developing immunotherapies against cancer, has secured $40m in funding from the Bill & Melinda Gates Foundation to boost its research activities in infectious diseases. The company hopes to develop novel therapeutics to reduce treatment timelines and improve outcomes for patients with HIV and TB.
Gates Foundation Invests In Immunocore For Development Of New Drugs To Benefit Global Population
The Bill & Melinda Gates Foundation is investing up to $40m in UK-based biotech Immunocore Ltd. for the discovery and development of soluble T-cell receptor therapies for tuberculosis (TB) and human immunodeficiency virus (HIV).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.
Roivant president Eric Venker was named CEO of Immunovant to guarantee execution of the development plan for IMVT-1402 in six indications, now including Sjögren’s disease and cutaneous lupus erythematosus.
